Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 15

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Dermatitis atopic88Malignant melanoma79Systemic lupus erythematosus61Psoriasis53Hidradenitis47Psoriatic arthropathy46Systemic scleroderma39Metastatic malignant melanoma32Vitiligo23Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis15Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+329

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Systemic scleroderma+2

Recruiting

Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Miltenyi Biomedicine GmbH

Renal cell carcinoma+1

Recruiting

Study on Nivolumab Dose Optimization for Patients with Melanoma or Renal Cell Carcinoma Showing Complete, Partial, or Stable Response

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Pemphigus

Recruiting

Study on Personalized Maintenance Therapy with Rituximab and Corticosteroids for Patients with Pemphigus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire Rouen

Thermal burn

Recruiting

Study on Antibiotic Prophylaxis with Piperacillin, Tazobactam, and Cefazolin for Burn Patients Undergoing Excision-Graft Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin
  • Sponsor:Assistance Publique Hopitaux De Paris

Neurofibromatosis

Recruiting

Study on Crizotinib for Treating Severe Neurofibromatosis Type 2 in Children Not Eligible for Surgery or Radiotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Crizotinib
  • Sponsor:Medical University Of Warsaw

Malignant melanoma

Recruiting

Study on the Effectiveness of Pembrolizumab and Ipilimumab in Melanoma Patients with Brain Metastases Requiring Steroid Treatment

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Region Hovedstaden

Psoriasis

Recruiting

Study on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Universitair Ziekenhuis Gent

Uveitis+1

Recruiting

Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Lymphangiosarcoma+34

Recruiting

Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ttf-Ngr
  • Sponsor:Universitaet Muenster

Thermal burn

Recruiting

Study on Glucose Use in Adults with Severe Burns

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Centre Hospital Region Metz Thionville

Dermatomyositis

Recruiting

Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Diabetic foot

Recruiting

Treatment Study of Diabetic Foot Ulcers Using Autologous Stromal Vascular Fraction Cells for Patients with Non-healing Wounds

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells
  • Sponsor:Centre Hospitalier Regional De Marseille

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.